Medical Cannabis Operators Face June 26 DEA Registration Deadline

The clock is ticking. On April 28, the Blanche rescheduling order took effect, moving state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). That change was significant. So was what it triggered: a mandatory Drug Enforcement Administration registration requirement for every state-licensed medical cannabis entity that manufactures, cultivates, processes, distributes, or dispenses medical marijuana or medical marijuana products. 

The DEA opened a 60-day expedited registration window when the rule took effect April 28. Because the 60th day falls on Saturday, June 27, operators should treat Friday, June 26, as the effective business deadline — and for most applicants, the practical deadline is sooner. 

If you handle state-licensed medical cannabis and have not yet filed a DEA registration application, this article is for you.

What the Blanche order changed

The reclassification to Schedule III means federal law no longer treats state-licensed medical cannabis as a substance with no accepted medical use and high abuse potential. It is now in the same category as anabolic steroids and ketamine — still a controlled substance, but not controlled to the point of prohibition. That is meaningful progress.

However, adult-use cannabis remains on Schedule I, in the same category with illegal drugs including heroin and LSD. The Blanche order covers only state-licensed medical cannabis and cannabis products approved by the Food and Drug Administration. Operators who handle both medical and adult-use must segregate their operations clearly and precisely, and the DEA registration requirement applies only to the medical side.

This distinction is not academic. An operator who conflates medical and adult-use inventory in their DEA registration filing is creating a federal compliance exposure, not resolving one.

Who needs a DEA registration

The registration requirement covers the full medical cannabis supply chain.

• Cultivators and manufacturers: entities growing or producing state-licensed medical cannabis plants or products.

• Distributors: entities moving medical cannabis between licensed facilities.

• Dispensaries: retail-facing entities dispensing medical cannabis to patients.

If your operation “handles” state-licensed medical cannabis products at any point in the supply chain, you need a DEA registration.

Operators who already hold DEA registrations — pharmacies, pharmaceutical manufacturers — should confirm with counsel whether their existing registration is sufficient or whether an amended or new registration for cannabis-specific Schedule III handling is required. Do not assume an existing registration covers this.

How to file a DEA registration application

Dispensary applicants should use DEA’s Medical Marijuana Dispensary Registration Portal; other applicants should follow DEA Diversion registration instructions for their activity type. Each dispensary application requires a nonrefundable fee of $794.

The application may be especially onerous for dispensaries, because DEA asks applicants to provide identifying information for all individuals anticipated to “have access to controlled substances,” including names, titles, dates of birth, Social Security numbers, and applicable DEA or state license numbers.  

Required documentation typically includes a state license, business entity information, and a description of the controlled substance handling activity. Confirm specific documentation requirements in the DEA’s diversion portal or through legal counsel.

What happens if you miss the deadline?

This is where operators need to understand the stakes clearly.

Existing licensed operators who miss the deadline lose the rule’s pending-application protection. That’s important, because the Rohrabacher-Blumenauer budget rider was omitted from the “One Big Beautiful Bill Act” federal budget package signed into law July 4, 2025. Since 2014, Rohrabacher-Blumenauer (formerly known as Rohrabacher-Farr) had barred the Department of Justice from using federal funds to interfere with state medical cannabis programs. The status of Rohrabacher-Blumenauer protections is no longer a clean fallback, and operators should not treat annual appropriations language as a substitute for CSA compliance. 

Consequently, operators need to be aware:

1. Operating without DEA registration while handling Schedule III cannabis becomes a federal violation.

2. Civil penalties may apply, including fines of up to $25,000 per violation for certain CSA violations, depending on the conduct.

3. Criminal exposure is possible for unauthorized handling of a Schedule III substance.

4. DEA may limit or deny future registration eligibility for existing state-licensed operators who fail to register before the June 26 deadline.

Legal challenges to the Blanche order pending in the U.S. Court of Appeals for the D.C. Circuit do not change this calculus. As of publication, no stay of the order appears to have been granted. The order remains in effect unless and until a court says otherwise.

Why registration strengthens compliance posture

For decades, the cannabis industry has operated under federal legal tolerance, not federal legal standing. Medical operators who register with the DEA will have a clearer federal compliance posture under the CSA than they had under Schedule I, but registration does not legalize adult-use activity or eliminate all federal risk. 

The registration window is a compliance requirement. It is also an opportunity to gain a level of operational security cannabis businesses have not experienced previously.

Action steps before the deadline

1. Gather your state license(s) and other required business documentation.
2. File at deadiversion.usdoj.gov before the deadline.
3. Target submission by June 22–25 — do not wait until June 26.

The window closes in days, not weeks.